Determinants of soluble CD23 antigen levels in hemodialysis patients: effect of 1.25 dihydroxyvitamin D3 and recombinant human erythropoietin treatment.

MLA

Altun, B., et al. “Determinants of Soluble CD23 Antigen Levels in Hemodialysis Patients: Effect of 1.25 Dihydroxyvitamin D3 and Recombinant Human Erythropoietin Treatment.” Clinical Nephrology, vol. 52, no. 4, Oct. 1999, pp. 230–38. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=10543325&authtype=sso&custid=ns315887.

APA

Altun, B., Erdem, Y., Usalan, C., Arici, M., Haznedaroglu, I. C., Yasavul, U., Turgan, C., Caglar, S., & Kirazli, S. (1999). Determinants of soluble CD23 antigen levels in hemodialysis patients: effect of 1.25 dihydroxyvitamin D3 and recombinant human erythropoietin treatment. Clinical Nephrology, 52(4), 230–238.

Chicago

Altun, B, Y Erdem, C Usalan, M Arici, I C Haznedaroglu, U Yasavul, C Turgan, S Caglar, and S Kirazli. 1999. “Determinants of Soluble CD23 Antigen Levels in Hemodialysis Patients: Effect of 1.25 Dihydroxyvitamin D3 and Recombinant Human Erythropoietin Treatment.” Clinical Nephrology 52 (4): 230–38. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=10543325&authtype=sso&custid=ns315887.